Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Gross Profit: 2020-2025

Historic Gross Profit for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to $15,000.

  • Lyell Immunopharma's Gross Profit fell 55.88% to $15,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $41,000, marking a year-over-year decrease of 34.92%. This contributed to the annual value of $61,000 for FY2024, which is 53.08% down from last year.
  • Per Lyell Immunopharma's latest filing, its Gross Profit stood at $15,000 for Q3 2025, which was up 87.50% from $8,000 recorded in Q2 2025.
  • Lyell Immunopharma's Gross Profit's 5-year high stood at $48.4 million during Q4 2022, with a 5-year trough of $3,000 in Q3 2022.
  • For the 3-year period, Lyell Immunopharma's Gross Profit averaged around $20,091, with its median value being $13,000 (2024).
  • As far as peak fluctuations go, Lyell Immunopharma's Gross Profit spiked by 1,614.60% in 2022, and later tumbled by 99.97% in 2023.
  • Quarterly analysis of 5 years shows Lyell Immunopharma's Gross Profit stood at $2.8 million in 2021, then skyrocketed by 1,614.60% to $48.4 million in 2022, then plummeted by 99.97% to $13,000 in 2023, then dropped by 15.38% to $11,000 in 2024, then slumped by 55.88% to $15,000 in 2025.
  • Its last three reported values are $15,000 in Q3 2025, $8,000 for Q2 2025, and $7,000 during Q1 2025.